Results 21 to 30 of about 66,215 (366)

Machine Learning Methods for Identifying Atrial Fibrillation Cases and Their Predictors in Patients With Hypertrophic Cardiomyopathy: The HCM-AF-Risk Model [PDF]

CJC Open, Volume 3, Issue 6, June 2021, Pages 801-813, 2021
Hypertrophic cardiomyopathy (HCM) patients have a high incidence of atrial fibrillation (AF) and increased stroke risk, even with low risk of congestive heart failure, hypertension, age, diabetes, previous stroke/transient ischemic attack scores. Hence, there is a need to understand the pathophysiology of AF and stroke in HCM.
arxiv   +1 more source

Myosin Inhibition and Left Ventricular Diastolic Function in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Insights From the VALOR-HCM Study

Circulation Cardiovascular Imaging, 2022
Background: In the randomized phase 3 VALOR-HCM study (A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Who Are Eligible for Septal Reduction Therapy) of patients with obstructive hypertrophic ...
P. Cremer, J. Geske, A. Owens, W. Jaber, S. Harb, S. Saberi, Andrew Wang, M. Sherrid, S. Naidu, H. Schaff, N. Smedira, Qiuqing Wang, K. Wolski, K. Lampl, A. Sehnert, S. Nissen, M. Desai   +16 more
semanticscholar   +1 more source

Impact of Race and Ethnicity on Use and Outcomes of Septal Reduction Therapies for Obstructive Hypertrophic Cardiomyopathy

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023
Background Information on impact of race and ethnicity on use and early outcomes of septal reduction therapies (SRTs) for obstructive hypertrophic obstructive cardiomyopathy are limited.
Sri Harsha Patlolla, Hartzell V. Schaff, Rick A. Nishimura, Mackram F. Eleid, Jeffrey B. Geske, Steve R. Ommen   +5 more
doaj   +1 more source

Identifying Ventricular Arrhythmias and Their Predictors by Applying Machine Learning Methods to Electronic Health Records in Patients With Hypertrophic Cardiomyopathy(HCM-VAr-Risk Model) [PDF]

The American Journal of Cardiology, Volume 123, Issue 10, 15 May 2019, Pages 1681-1689, 2021
Clinical risk stratification for sudden cardiac death (SCD) in hypertrophic cardiomyopathy (HC) employs rules derived from American College of Cardiology Foundation/American Heart Association (ACCF/AHA) guidelines or the HCM Risk-SCD model (C-index of 0.69), which utilize a few clinical variables.
arxiv   +1 more source

Cardiac Myosin Inhibitors as a Novel Treatment Option for Obstructive Hypertrophic Cardiomyopathy: Addressing the Core of the Matter

Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease, 2022
mid- ventricular, and post- SRT phenotypes. Patients with heart failure with preserved ejection fraction also represent a future target for CMIs given their mechanism of action.
Ahmad Masri, I. Olivotto
semanticscholar   +1 more source

Neonatal hypertrophic cardiomyopathy with dyspnoea as the first symptom: a case report

Frontiers in Pediatrics, 2023
Neonatal hypertrophic cardiomyopathy (HCM) is an idiopathic disease characterised by myocardial hypertrophy with normal or small ventricular chambers, a systolic hyperdynamic state and diastolic dysfunction.
Xiaoxia Li, Shu-Jun Hong, Hui Hong, Zhi-Qun Zhang, Jing Li   +4 more
doaj   +1 more source

Mega Coronary Arteries with Obstructive Coronary Artery Disease in Hypertrophic Obstructive Cardiomyopathy: A Case Report and Literature Review

Journal of the Indian Academy of Echocardiography & Cardiovascular Imaging, 2022
We report a rare case of hypertrophic obstructive cardiomyopathy (HOCM) presenting with mega coronary arteries with obstructive coronary artery disease.
Debasish Das, Debasis Acharya, Tutan Das, Subhas Pramanik   +3 more
doaj   +1 more source

Effect of beta‐blocker therapy on the response to mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy

European Journal of Heart Failure, 2022
In the EXPLORER‐HCM trial, mavacamten improved exercise capacity and symptoms in patients with obstructive hypertrophic cardiomyopathy (oHCM). Mavacamten effects on the primary endpoint, a composite of peak oxygen consumption (VO2) and New York Heart ...
M. Wheeler, D. Jacoby, P. Elliott, S. Saberi, Sheila M. Hegde, N. Lakdawala, J. Myers, A. Sehnert, J. Edelberg, Wanying Li, I. Olivotto   +10 more
semanticscholar   +1 more source

Individualized interactomes for network-based precision medicine in hypertrophic cardiomyopathy with implications for other clinical pathophenotypes

Nature Communications, 2021
Progress in precision medicine is limited by insufficient knowledge of transcriptomic or proteomic features in involved tissues that define pathobiological differences between patients.
Bradley A. Maron, Rui-Sheng Wang, Sergei Shevtsov, Stavros G. Drakos, Elena Arons, Omar Wever-Pinzon, Gordon S. Huggins, Andriy O. Samokhin, William M. Oldham, Yasmine Aguib, Magdi H. Yacoub, Ethan J. Rowin, Barry J. Maron, Martin S. Maron, Joseph Loscalzo   +14 more
doaj   +1 more source

An Unusual Case of Shock in an Octogenarian [PDF]

Annals of Geriatric Medicine and Research, 2021
An octogenarian presented to our hospital in shock after being “found down” at home. She was dehydrated, hypernatremic, and suffering from a urinary tract infection.
Michael A. Chen
doaj   +1 more source